Volume 71, Issue 6, Pages (June 2017)

Slides:

Advertisements

Similar presentations

Volume 70, Issue 3, Pages (September 2016)

Advertisements

The PSA Era is not Over for Prostate Cancer

Volume 68, Issue 6, Pages (December 2015)

Volume 50, Issue 1, Pages (July 2006)

Volume 51, Issue 2, Pages (February 2007)

Volume 69, Issue 3, Pages (March 2016)

Volume 72, Issue 5, Pages (November 2017)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 44, Issue 6, Pages (December 2003)

Testosterone Therapy in Men With Prostate Cancer

Global Trends in Testicular Cancer Incidence and Mortality

Volume 70, Issue 1, Pages (July 2016)

Prostate Cancer: Highlights from 2006

Volume 49, Issue 2, Pages (February 2006)

Volume 61, Issue 5, Pages (May 2012)

Volume 74, Issue 2, Pages (August 2018)

Volume 53, Issue 5, Pages (May 2008)

Volume 69, Issue 1, Pages (January 2016)

Volume 51, Issue 4, Pages (April 2007)

Volume 69, Issue 1, Pages (January 2016)

Volume 70, Issue 2, Pages (August 2016)

Volume 199, Issue 6, Pages (June 2018)

Volume 71, Issue 5, Pages (May 2017)

Volume 73, Issue 5, Pages (May 2018)

Prostate Cancer Epidemic in Sight?

Volume 63, Issue 4, Pages e53-e56 (April 2013)

Volume 68, Issue 1, Pages (July 2015)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 67, Issue 2, Pages (February 2015)

Volume 63, Issue 6, Pages (June 2013)

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 68, Issue 3, Pages (September 2015)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 67, Issue 6, Pages (June 2015)

Volume 71, Issue 5, Pages (May 2017)

Volume 70, Issue 5, Pages (November 2016)

Volume 73, Issue 4, Pages (April 2018)

Volume 53, Issue 4, Pages (April 2008)

Volume 64, Issue 6, Pages (December 2013)

Prostate Cancer Epidemic in Sight?

Thromboembolic Events Following Surgery for Prostate Cancer

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 74, Issue 2, Pages (August 2018)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 66, Issue 2, Pages (August 2014)

Volume 58, Issue 1, Pages 1-7 (July 2010)

Volume 63, Issue 3, Pages (March 2013)

Volume 62, Issue 4, Pages (October 2012)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 70, Issue 2, Pages (August 2016)

Volume 50, Issue 5, Pages (November 2006)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Prostate Cancer Nomograms: An Update

Volume 71, Issue 5, Pages (May 2017)

Volume 71, Issue 3, Pages (March 2017)

Testicular Cancer Variations in Time and Space in Europe

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

European Urology Oncology

Long-Term Hormonal Therapy: Who Would Benefit?

Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer Felix Preisser, Michele Marchioni, Sebastiano.

Volume 75, Issue 3, Pages (March 2019)

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Volume 74, Issue 6, Pages (December 2018)

Volume 51, Issue 2, Pages (February 2007)

Volume 54, Issue 3, Pages (September 2008)

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 71, Issue 6, Pages 907-912 (June 2017) New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8–10 Prostate Cancer Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, Bruce J. Trock, Jonathan I. Epstein, Carling Cheung, Elizabeth Humphreys, Alan W. Partin, Misop Han European Urology Volume 71, Issue 6, Pages 907-912 (June 2017) DOI: 10.1016/j.eururo.2016.11.006 Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 1 Flowchart for study inclusion. RP=radical prostatectomy; GS=Gleason score; Bx=biopsy. European Urology 2017 71, 907-912DOI: (10.1016/j.eururo.2016.11.006) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 2 Cumulative incidence functions for prostate cancer–specific mortality for biopsy (Bx) Gleason score (GS) 8 versus 9–10. HR=hazard ratio; CI=confidence interval. European Urology 2017 71, 907-912DOI: (10.1016/j.eururo.2016.11.006) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 3 Cumulative incidence functions for prostate cancer–specific mortality for radical prostatectomy (RP) Gleason score (GS) 8 versus 9–10. HR=hazard ratio; CI=confidence interval. European Urology 2017 71, 907-912DOI: (10.1016/j.eururo.2016.11.006) Copyright © 2016 European Association of Urology Terms and Conditions